Principles of management of extremity skeletal metastasis
Correspondence Address: Source of Support: None, Conflict of Interest: None DOI: 10.4103/IJPC.IJPC_90_19
Source of Support: None, Conflict of Interest: None
Keywords: Angioembolization, endoprosthesis, megaprosthesis, pathological fracture, radiotherapy, skeletal metastasis
Bone is the third most frequent site of metastatic disease and primary tumors from breast, lung, prostate, renal cancers and thyroid are the most common cause of bone metastases. The primary presentation is pain and pathological fracture in 9%–29% of cases, with about 90% of pathological fractures requiring intervention., The orthopedic management of these bone metastasis have a major impact on both quality of life and probably survival rates.
In this article, we review extremity bone metastases which accounts for 66% of skeletal metastasis. Extremity metastases are one of the first presentations of disease in lung cancer, renal cancer, myeloma, and lymphoma, with a median survival from diagnosis of: 6 months in melanoma, 6–7 months in lung, 6–9 months in bladder, 12 months in renal cells carcinoma, 12–53 months in prostate, 19–25 months in breast, and 48 months in thyroid. The treatment involves a multidisciplinary team input which includes an orthopedic surgeon, orthopedic oncologist, radiologist, radiation oncologist, medical oncologist, and other health-care personnel. The treatment varies on the specific site of involvement and is important that health-care personnel, especially orthopedic surgeons, are updated with recent trends in the management of skeletal metastasis. In this article, we highlight the principles of management and decision-making in treatment of skeletal metastasis in the extremity.
Commonly involving the axial skeleton, bone metastasis present at multiple sites. This could be in relation to the hematopoietically-active red bone marrow and the paravertebral network that may play a role in metastasis. Apart from the favorable microenvironment for tumor cell survival, the following are needed ones the tumor cells are in circulation,,,
The golden rule stating that a complete workup must precede surgery, should be respected in the setting of a pathological fracture. It can present as the first sign of an unknown primary or be seen in cases with an established primary diagnosis. In cases with an established primary, the diagnosis of a second primary bone tumor as a differential diagnosis should always be considered. Clinical features of multiplicity and typical axial preference point toward bone metastases. Biopsy should, however, be done to confirm the diagnosis before planning any intervention.
A painful solitary bone lesion without history of metastatic disease or a primary malignancy needs a more extensive metastatic workup which include laboratory investigations and imaging before the biopsy. Some of the commonly used laboratory investigations are: β2- microglobulin, urine for Bence–Jones proteins and serum electrophoresis for multiple myeloma, CA-19.9 for pancreatic and biliary tumors, CA-125 for ovarian cancer, prostate-specific antigen (PSA) for prostate cancer, CA-15.3/CA-27.29 for breast cancer, carcinoembryonic antigen for colorectal and breast cancer, and calcitonin for medullary thyroid cancer. Imaging includes plain radiographs, bone scan, computerized tomography scan (CT), magnetic resonance imaging (MRI), and fluoride/fluorodeoxyglucose-positron emission tomography (PET) scan. Imaging may reveal an easier to access biopsy site or direct the tract for a percutaneous biopsy. Possibility of bone sarcomas should be considered in cases with a history of prior radiation exposure such as Paget's disease and fibrous dysplasia. The final management and survival depend on the primary tumor.
Irrespective of the primary tumor, presence of skeletal metastases, visceral metastases, and multiplicity is associated with poor prognosis.,, Prognosis in metastatic bone cases depends on various factors. For those arising from breast cancer, the extraosseous disease, disease-free interval, performance status, estrogen receptor status, age, and histologic grade play a role in prognosis. While in skeletally metastatic prostate cancer, the performance status, extraosseous disease, fall in alkaline phosphatase, and PSA levels are well-approved prognostic factors.
In multiple myelomas, β2- microglobulin and C-reactive protein are the main independent prognostic factors with the median survival of 6 months for those with high levels and 54 months for those with low levels.
Using predictive models like Bayesian Belief Network, patient's survival can be predicted which helps us in deciding the final treatment plan. The clinical data are used to calculate survival at 3 and 12 months. For those with survival < 3 months, surgical management is not recommended, those with 3–12 months of survival may require less invasive procedures without long rehabilitation and those with > 12 months of survival, a more durable reconstruction method is recommended.
In a study done by Bauer, it was reported that the overall survival of those who underwent fixation for pathological fracture was <6 months and was similar to those who received radiotherapy (RT) for bone pain., The incidence of solitary metastases is lower compared with those with multiple metastases, with solitary metastases having better prognosis than those with multiple metastases.,
Five-year survival rate of skeletal metastasis is shown in [Table 1].
Mechanical strength prediction
Prediction of mechanical strength and the risk of pathological fracture are considered to be an important variable for decision-making when managing bone metastases. Mirel's scoring system is one of the most commonly used systems to predict the risk of pathological fracture [Table 2]. The risk of fracture was 33% for a patient with a score of 9, 15% for a patient with a score of 8, an 4% for a patient with a score of 7. Excessive pain is one of the most significant indicators for an impending pathological fracture. At times, plain radiography alone is not diagnostic or a predictor of impending fractures. More than 50% of trabecular bone should be destroyed to be evident on radiograph. In such cases, significant pathological fracture risk should be considered. Cases with lesser trochanter avulsion indicate an impending hip fracture. CT rigidity analysis (CTRA) is a novel method of predicting the pathological fracture probability, wherein the density of the bone and the cross-sectional area at maximal weakness point are recorded to estimate bending, torsion, and axial rigidity. The data are then compared with a gender- and size-matched normal femur CT. Reduction in axial, bending, or torsional rigidities >35% was considered a significant risk for fracture.
CTRA reported better sensitivity, specificity, and PPV and NPV over Mirel's Scoring System.
Skeletal metastases are seldom an emergency. The goal of treatment would be to get the patient back to their previous activity level. The following are the treatment strategies available.
The most common debilitating symptom of a malignancy is pain which causes significant impact on the daily activity and social life. Pain can be due to osteoclast activation, substances produced by tumor cells, surrounding inflammatory reaction due to tumor growth and invasion into surrounding tissues and nerve compression. Pain management has various treatment modalities along with histology-specific treatment, namely, nonsteroidal anti-inflammatory drugs, bisphosphonates, opioids, tricyclic antidepressants, RT, and surgical management.
Osteoclast activation has an essential role in the destruction of bone with metastases. Receptor-activated nuclear factor kappa-B ligand (RANKL) attracts tumor cells into the bone to produce more RANKL. This increases the osteoclasts leading to accelerated bone destruction. Bisphosphonates therapy has become commonly used to reduce morbidity among patients with skeletal metastases. However, they benefit the patient by only 30%–40% with complications such as osteonecrosis of the jaw and may require intravenous administration.
Denosumab, a monoclonal antibody against RANKL has shown improved efficacy in blocking osteoclast formation and osteoclast-mediated bone destruction. It is administered subcutaneously and is not excreted through the kidney, an advantage for patients with chronic kidney disease. Denosumab was reported to be superior to zolendronic acid with relation to reduction of the skeletal-related events. Both had similar results regarding the quality of life, pain, and overall survival. However, bisphosphonates have an additional antitumor action which may add to survival, especially in breast cancer.
RT is frequently used for palliation of pain in bone metastases with reports of complete pain relief in one-third of the patients. More than 50% of them have pain relief beyond 6 months. Studies have shown that short-course regimen with 8 Gray (Gy) as single fraction dose is as effective as the long-course RT regimens. Jeremic et al. have compared short course RT regimens (4 Gy vs. 6 Gy vs. 8 Gy) and concluded that 8 Gy is the “lowest” optimal single fraction.
Hartsell et al. compared the 8 Gy in a single fraction with 30 Gy in 10 fractions in 898 patients and reported comparable results with regard to pain and narcotic relief. The risk of pathologic fracture was 5% in 8-Gy group and in 4% in 30-Gy group. However, the 8-Gy group had a retreatment rate higher than the 30-Gy group (18% vs. 9%, P < 0.001).
The protective role of RT from pathological fractures has not been well defined. Comparison between the outcomes of the surgical fixation of pathological fractures with or without RT has been done with a conclusion that postoperative RT is the only significant predictor for a successful outcome.
RT starts within 2 weeks postoperative and covers the entire operative field and the whole length of the implant. However, the role of RT is limited in those cases with endoprosthesis replacements with one study reporting poor bone remodeling distal to prosthesis and less new bone formation around the prosthesis.
Depending on the aim of intervention, intralesional curettage, marginal excision, or wide excision can be done. Preoperative embolization can be done while dealing with vascular tumors such as skeletal metastases from renal cell carcinoma or simply to facilitate en bloc excision. Solitary lesions should be treated with curative intent with added emphasis on functional recovery and pain control.
The general rule in reconstruction is to protect the whole length of the bone to avoid failure in cases of recurrence. Plating, nailing, or endoprosthesis can be used. Locked compression plates fixed using minimally invasive techniques have maximal benefits in metastatic fixations. Locked plates reduce the risk of pullout or loosening with reduced postoperative morbidity due to minimally invasive approach.
Since the lesion is not expected to heal, bone cement is used for augmentation of the fixation instead of allografts and biological cement types. Bone cement facilitates early weight bearing with improved postoperative pain and function.
For lesions involving the diaphysis, intramedullary nailing can be done. Titanium nails have the advantage of improved mechanical strength with smaller diameter. Repair or reconstruction of the capsule and reattachment of surrounding soft tissue to the implant (rotator cuffs, external rotators) should be done to achieve good functional strength, range of movement, and joint stability. 15% to 20% of those treated with surgery will have disease progression and loss of fixation, thus postoperative radiation is recommended.
Enneking classified the pelvis into three distinct zones. Zone 1 and 3 are nonweight bearing and expendable bones. Lesions involving Zone 2 alone or in combination with adjacent bones, require curettage with cementing or reconstruction with custom made or modular mega prosthesis, saddle prosthesis, or total hip replacements combined with multiple Steinmann pins and cement (Harrington technique). In lesions requiring resection of Zone 2 and 3, an inverted ice cream cone prosthesis or pedestal cup can be used.
The proximal femur is the most common site for bone metastases involving a significant risk of mechanical failure, hampering the quality of life. For lesions involving head or neck of the femur [Figure 1] and [Figure 2] the choice of treatment is typically a bipolar hemiarthroplasty with a long stem. For lesions involving the acetabulum or associated with large mass (e.g., trochanteric and peri trochanteric regions), endoprosthesis gives best results. This facilitates early weight bearing and return to function with a lower failure rate.,
For femoral and tibial diaphyseal lesions, nailing [Figure 3] can be done along with curettage and cementing. To avoid failure due to recurrence in the neck, reconstruction nails can be used and the entire length of the bone should be spanned. In lesions involving the distal femur [Figure 4] and proximal tibia, composite total knee replacement can be done. For lesions involving the proximal tibia, the management principles are essentially similar to the femur and depend on the size of the lesion varying from curettage to resection and megaprosthesis.
The humerus is the second most common site of long bone metastases after the proximal femur. Mechanical stress on the humerus is far less than on the lower limb, and this is the reason why humeral bone metastases can be managed nonoperatively by external beam irradiation. Proximal humerus hemiarthroplasty can be used in cases with lesions, involving the proximal humeral head or neck provided the greater tuberosity, lesser tuberosity, and axillary nerve are intact. Proximal humerus endoprosthesis [Figure 5] or nail cement spacer with meshplasty can be done in large lesions involving proximal half of the humerus. Subluxation of the humeral head can be avoided by soft-tissue repair. For lesions spanning 2–3 cm distal to greater tuberosity and 5 cm proximal to olecrenon fossa, intramedullary nailing is recommended. Distal humeral metastases can be managed with plating and cement augmentation or total elbow replacement for large lesions involving joint. Nail cement spacer can be used for segmental defects of long bones. More than 90% of patients with humeral metastases have pain relief and functional restoration for activities of daily living irrespective of the management method. Functionally, they have restricted range of movements of the shoulder with normal functioning of the elbow and wrist. Lesions involving the scapula, a total or partial scapulectomy, can be planned based on the extent of involvement. The forearm is a relatively uncommon site for metastasis which may require resection of the involved bone.
Minimal invasive modalities
Radiofrequency ablation, cryoablation, and high-intensity focused ultrasound and microwave therapy are the percutaneous modalities which can be used to relieve the pain and improve bone strength without additional risk of morbidity from open surgery., Cementoplasty plays a vital role in lesions involving the pelvis [Figure 6]. They help by preventing a fracture and provide significant pain relief and functional improvement in 80% of cases. In endovascular techniques, angioembolization can provide devascularization and tumor necrosis. Embolization coupled with antimitotic agents (mainly adriamycin and platinum) prolongs the analgesia and can produce partial-to-complete tumoral remission.
Extremity metastases require adequate work-up and a biopsy to confirm the diagnosis. Management involves a multidisciplinary approach and cannot be generalised. It depends on the primary tumour and the expected survival. The aim of treatment can range from pain relief by medical management or radiotherapy and curative intent in cases with solitary metastases. The final aim should of course be to improve the patient's quality of life.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]
[Table 1], [Table 2]